GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stereotaxis Inc (AMEX:STXS) » Definitions » Gross-Profit-to-Asset %

Stereotaxis (Stereotaxis) Gross-Profit-to-Asset %

: 25.34% (As of Dec. 2023)
View and export this data going back to 2004. Start your Free Trial

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Stereotaxis's annualized Gross Profit for the quarter that ended in Dec. 2023 was $10.95 Mil. Stereotaxis's average Total Assets over the quarter that ended in Dec. 2023 was $43.22 Mil. Therefore, Stereotaxis's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 25.34%.


Stereotaxis Gross-Profit-to-Asset % Historical Data

The historical data trend for Stereotaxis's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stereotaxis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.32 38.30 39.90 32.29 31.18

Stereotaxis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.48 29.78 33.83 34.98 25.34

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Stereotaxis's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stereotaxis Gross-Profit-to-Asset % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Stereotaxis's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Stereotaxis's Gross-Profit-to-Asset % falls into.



Stereotaxis Gross-Profit-to-Asset % Calculation

Stereotaxis's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=14.86/( (53.413+41.909)/ 2 )
=14.86/47.661
=31.18 %

Stereotaxis's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=10.952/( (44.528+41.909)/ 2 )
=10.952/43.2185
=25.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Stereotaxis Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Stereotaxis's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Stereotaxis (Stereotaxis) Business Description

Traded in Other Exchanges
Address
710 North Tucker Boulevard, Suite 110, St. Louis, MO, USA, 63101
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.
Executives
Paul J Isaac 10 percent owner 530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Myriam Curet director 1020 KIFER ROAD, SUNNYVALE CA 94086
David Benfer director 5 SELDEN AVENUE, BRANFORD CT 06404
Kimberly R. Peery officer: Chief Financial Officer C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE: SUITE 100, ST. LOUIS MO 63108
Kevin M. Barry officer: Chief Legal Officer & Secretar 4320 FOREST PARK AVENUE, 100, ST. LOUIS MO 63108
Ross B Levin director 530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Fariba Fischel Ghodsian 10 percent owner 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Dafna Capital Management Llc 10 percent owner 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
David Leo Fischel director 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Arun Swarup Menawat director 2412 EIGHTH LINE, OAKVILLE A6 L6H6S9
Joe E Kiani director 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Paul Brathwaite officer: VP Research & Development C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Martin C Stammer officer: Chief Financial Officer C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Nathan Fischel director 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Duane Desisto director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730